Arrowhead Pharma (ARWR) Stock Price, Quote & News

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology

Sector: Healthcare

Phone: 626 304 3400

Fax: 626 304 3401

Website: arrowheadpharma.com

Address:

177 East Colorado Boulevard, Suite 700, Pasadena, United States

skeezbag Aug. 18 at 4:26 PM

$ARWR JP Morgan still won't let me change my 64.5 tattie to 87 fwiw

0 · Reply

johnnygogogo Aug. 18 at 2:37 PM

$ARWR me telling the kiddos that the “87” and the “TWAP” are the cool new dance moves. @skeezbag

1 · Reply

skeezbag Aug. 18 at 1:53 PM

$ARWR I guess the arrowhead semiconductors are dog shit

0 · Reply

Merlintrader Aug. 18 at 9:48 AM

Arrowhead Pharmaceuticals ($ARWR) Stock Hub 2026: REDEMPLO Launch, Positive SHASTA Phase 3 Data, YOSEMITE Enrollment And A $1.78B Liquidity Base https://www.merlintrader.com/arrowhead-pharmaceuticals-stock-hub/

0 · Reply

JFais Aug. 17 at 8:50 PM

I've missed so many prime setups like $RVMD over the past year or so... Also, other winners like $ARWR $AXSM $IOVA I sold too early Key takeaway for me is actually quite encouraging! Namely, that I can have this kind of + performance over a decent stretch despite my mistakes

1 · Reply

NeverFadeTheOracle Aug. 17 at 7:17 PM

$ARWR

0 · Reply

G101SPM Aug. 17 at 1:49 PM

$ARWR $87.11 bid. DAC (dollar average cost is zero, created by partial SELLS to reduce net investment cost. https://stocktwits.com/search/u/G101SPM?symbol=ARWR BRIEF: REDEMPLO (plozasiran) is now listed in Germany's Lauer-Taxe database, allowing prescribing, dispensing and reimbursement following EU approval in June 2026. The drug is authorized as an adjunct to diet to reduce triglycerides in adults with familial chylomicronaemia syndrome diagnosed by clinical symptoms or genetic test. Arrowhead said Germany is its first EU launch focus and it is working to expand availability in other European countries over the coming months. EU authorization was supported by the Phase 3 PALISADE study, where plozasiran significantly reduced median fasting triglycerides at the 25 mg dose versus placebo at Month 10.

0 · Reply

Valueforall Aug. 16 at 1:47 PM

$SRPT $ARWR Block out the short-seller noise, because Sarepta's game-changing future isn't tied to a single gene-therapy narrative. Their multi-billion-dollar Arrowhead alliance locks up the targeted TRiM siRNA engine, handing them clean muscle delivery for DM1 (⁠SRP-1003⁠), first-in-class upstream DUX4 silencing for FSHD (⁠SRP-1001⁠), and a non-viral CNS pipeline for diseases like Ataxia. You aren't holding a broken chart -you're indirectly holding the undisputed king of rare disease RNA

1 · Reply

CDMO Aug. 15 at 6:01 AM

$ARWR september will be a very catalyst rich month. >100 incoming imo

1 · Reply

skeezbag Aug. 14 at 7:26 PM

$ARWR hello babysitters

1 · Reply

Market Cap	12.49B
Revenue (ttm)	829.45M
Net Income (ttm)	-1.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-0.20%
Debt to Equity Ratio	1.85

Volume	972,000
Avg Vol	2,218,568
Day's Range	N/A - N/A
Shares Out	140.86M
Stochastic %K	57%
Beta	1.27
Analysts	Strong Sell
Price Target	$108.08